Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with a specific form of wet age-related macular degeneration (AMD) where abnormal blood vessel growth is located behind the central part of the retina, in one or both eyes (only one eye per patient will be studied)
- People who are planned to receive injections into the eye of one of the following medicines: Bevacizumab, Ranibizumab, or Aflibercept
- People of childbearing age who are using effective contraception
- People who have been informed about the study and have not objected to taking part
- People who are covered by a social security scheme
Who may not be able to join:
- People who have received previous treatment for AMD by injection into a vein or eye surgery within the last 2 months in the eye being studied
- People for whom Bevacizumab, Ranibizumab, or Aflibercept are medically unsuitable
- People who are missing the natural lens in the eye being studied
- People who have scarring or tissue loss behind the central area of the retina in the eye being studied
- People who have a tear in a specific layer of the retina (the pigment epithelium) that reaches the central area of the eye being studied
- People whose abnormal blood vessel growth in the eye is caused by something other than AMD
- People who have a confirmed diagnosis of diabetic retinopathy and/or diabetic damage to the central part of the retina
- People whose blood sugar control measure (glycated haemoglobin) is greater than 12%
- People with a known allergy or sensitivity to any of the medicines used in the trial
- Women who are pregnant or breastfeeding
- People with severe active inflammation inside the eye, or a history of a condition called autoimmune or idiopathic uveitis (inflammation inside the eye)
- People with an active or suspected infection in or around the eye
- People with eye pressure above 25 mmHg even after using two different pressure-lowering eye drop treatments
- People who are under a legal guardianship or protection arrangement (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sophie BRYSELBOUT, Dr, CHU Amiens
Phone: 33 3 22 08 92 19
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cost-utility analysis of the modalities of management of neovascular age-related macular degeneration
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.